ParinGenix Inc.
ParinGenix Inc. was founded to develop 2-O, 3-O desulfated heparin, a nonanticoagulant heparin derivative, for the treatment of inflammatory diseases. The company has advanced the drug through Phase II clinical trials for the treatment of COPD.
Investors
- Research Corporation Technologies
- CHL Medical Partners (Stamford, Conn.)
- Domain Associates LLC (Princeton, N.J.)
- Aurora Funds (Durham, N.C.)
Inventors/Founders
Thomas Kennedy, M.D.
Carolinas Medical Center